Placental determinants of neonatal immune function in maternal HIV infection

孕产妇艾滋病毒感染中新生儿免疫功能的胎盘决定因素

• 批准号: 9900843
• 负责人: IRINA BURD
• 金额: $ 21.25万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9900843
• 关键词: Acute; Adaptive Immune System; Address; Affect; Algorithms; Antibodies; BCG Vaccine; Biopsy; Birth; Blood; Blood specimen; CD8-Positive T-Lymphocytes; CD8B1 gene; Caring; Cells; Cellular Immunity; Child; Chronic; Clinical Data; Communicable Diseases; Data; Decidua Basalis; Development; Disease; Enrollment; Exposure to; Fc Receptor; Flow Cytometry; Funding; HIV; HIV Infections; HIV-exposed uninfected infant; Haemophilus influenzae; Health; Humoral Immunities; Immune; Immune response; Immune system; Immunity; Immunologic Markers; Immunologics; Immunology; Impairment; India; Infant; Infant Mortality; Infection; Inflammation; Inflammatory Response Pathway; Intervention; Lead; Life; Longevity; Maternal antibody; Mother-to-child HIV transmission; Mothers; Mus; National Institute of Child Health and Human Development; Neonatal; Newborn Infant; Outcome; Peripheral; Peripheral Blood Mononuclear Cell; Placenta; Play; Population; Postpartum Period; Pregnancy; Pregnant Women; Process; Production; Ramp; Regulatory T-Lymphocyte; Reporting; Risk; Role; Sampling; Schedule; Stains; Stimulus; Stratification; Streptococcus pneumoniae; Technology; Testing; Tuberculosis; Umbilical Cord Blood; United States National Institutes of Health; Vaccines; Viral; Viral Load result; Viremia; Vulnerable Populations; Woman; adaptive immunity; antiretroviral therapy; biobank; cohort; cytokine; design; fetal programming; fetus at risk; healthy pregnancy; immune function; improved; in utero; influenzavirus; neonatal Fc receptor; neonatal immune system; neonate; neuroinflammation; offspring; pathogen; pregnant; prenatal testing; prevent; pup; receptor expression; respiratory; response; screening; vaccine efficacy

ABSTRACT: HIV-exposed but uninfected (HEU) infants are twice as likely to die as HIV-unexposed and uninfected infants (HUU), mainly from other infectious diseases. There is an urgent need to understand how maternal HIV infection–whether controlled or not– impacts the development of the neonatal immune system. With this information, we can develop algorithms to prevent infectious diseases in HEU that account for their functional immune deficits. We hypothesize that maternal HIV infection results in inflammation of the placenta, decreased maternal-to- child transfer of antibodies, and differential programming of the neonatal immune system that impairs the immune response to vaccines. To test this hypothesis, we will integrate clinical data with immunologic data we will obtain from maternal, placenta and neonatal samples that were collected as part of an NIH-funded R01 study we have been conducting in India since 2014. We enrolled a unique, well-defined cohort of maternal- infant pairs with and without HIV and followed them longitudinally through pregnancy and the first year postpartum. We propose to capitalize on these stored samples to address the following aims: Aim 1. Compare the Treg/CD8+ T cell ratio in maternal blood, placenta, and cord blood samples by maternal HIV status and viral load. This aim will establish the relationship between immune cells and cytokines in maternal blood, placenta and cord blood samples, using flow cytometry, immunecard technology and immunohistochemical staining. Understanding how maternal and placental immunology relate to neonatal immune development may help us predict which infants will have impaired immune responses to pathogens. Aim 2. Determine the effect of placental immune function on infants’ humoral and cellular immunity. This aim will (1) identify how HIV decreases the transplacental transfer of antibodies to key respiratory pathogens involved in HEU infant mortality, including S. pneumoniae, H. influenzae, and influenza virus; and (2) determine if placental inflammation impacts the longevity of the infant’s immune response to BCG vaccine. Using these data, we can develop screening tests to predict which neonates will have the greatest immune compromise at birth. Studying the role of the placenta in the development of the neonatal immune system may also reveal key differences between HEU and HUU infants that will allow us to optimize care for this vulnerable population.

摘要：暴露于艾滋病毒但未感染（HEU）的婴儿死亡的可能性是未暴露于艾滋病毒的婴儿的两倍， 未感染的婴儿（HUU），主要来自其他传染病。迫切需要了解如何 孕产妇艾滋病毒感染--无论是否得到控制--都会影响新生儿免疫系统的发育。 有了这些信息，我们可以开发算法来预防高浓缩铀中的传染病， 功能性免疫缺陷 我们假设母体HIV感染会导致胎盘炎症，降低母体对 抗体的儿童转移，以及新生儿免疫系统的差异编程， 对疫苗的免疫反应。为了验证这一假设，我们将整合临床数据和免疫学数据， 将从作为NIH资助的R 01的一部分收集的母体、胎盘和新生儿样本中获得 自2014年以来，我们一直在印度进行研究。我们招募了一个独特的，定义明确的产妇队列- 对携带和不携带艾滋病毒的婴儿进行纵向跟踪， 产后我们建议利用这些储存的样本来实现以下目标： 目标1.比较母血、胎盘和脐带血样本中的Treg/CD 8 + T细胞比率， 母亲的艾滋病毒状况和病毒载量。这一目标将建立免疫细胞与 母血、胎盘和脐带血样本中的细胞因子，使用流式细胞术、免疫卡技术 免疫组化染色。了解母体和胎盘免疫学与新生儿的关系 免疫发育可以帮助我们预测哪些婴儿对病原体的免疫反应会受损。 目标2.胎盘免疫功能对新生儿体液免疫和细胞免疫功能的影响 免疫力这一目标将（1）确定艾滋病毒如何减少抗体的经胎盘转移， 涉及高浓缩铀婴儿死亡率的呼吸道病原体，包括沙门氏菌。pneumoniae，H.流感和流感 （2）确定胎盘炎症是否影响婴儿对病毒的免疫反应的寿命。 卡介苗。 利用这些数据，我们可以开发筛选测试，以预测哪些新生儿将具有最大的免疫力 出生时的妥协研究胎盘在新生儿免疫系统发育中的作用， 还揭示了高浓缩铀和高浓缩铀婴儿之间的关键差异，这将使我们能够优化对这一弱势群体的护理。 人口